PPARG and cancer: Thus, the combination of MEK inhibitors to enable differentiation with PPARγ agonist, to induce adipogenesis can result in cancer trans-differentiation into bona fide adipocytes (Tontonoz et al., 1997; Demetri et al., 1999; Debrock et al., 2003; Ishay-Ronen and Christofori, 2019; Ishay-Ronen et al., 2019).